A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK)
To find out if the combination of HC-7366 and nivolumab (with or without ipilimumab) can help to control ccRCC. The
Trial Details
- NCT ID
- NCT07401875
- Phase
- PHASE1
- Sponsor
- M.D. Anderson Cancer Center
- Status
- RECRUITING
- Cancer Type
- Kidney Cancer
- Interventions
- Nivolumab
- HC-7366
- ipilimumab
- Locations (sample)
- Houston, Texas, United States|29.76328,-95.36327
Key Eligibility Criteria
- Eligibility Criteria
- Ability to understand and the willingness to sign a written informed consent document
- Male or female ≥ 18 years of age
- Confirmed diagnosis of clear cell RCC
For full eligibility, visit ClinicalTrials.gov.
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Kidney Cancer Trials on Trialify →